ChromaDex & Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line & Advancing Global Retail Par...
November 09 2020 - 6:32AM
Business Wire
ChromaDex and Watsons Hong Kong launch new TRU NIAGEN® EX stick
packs for on-the-go consumers in new delivery method
ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive
launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong,
available online and in all Watsons Hong Kong stores. TRU NIAGEN®
has been the #1 selling supplement in Watsons Hong Kong, and TRU
NIAGEN® EX offers an alternative delivery method for the
well-studied healthy aging vitamin, available to mix with one’s
favorite beverage or sports drink.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201109005305/en/
TRU NIAGEN® EX launches in Watsons Hong
Kong (Graphic: Business Wire)
“The health-oriented customers at Watsons have made TRU NIAGEN®
a best-selling product in Hong Kong,” says ChromaDex CEO Rob Fried.
“TRU NIAGEN® EX will help us reach the active, fitness-oriented
consumer who drinks sports beverages and protein shakes.”
ChromaDex and A.S. Watson Group have been in partnership since
2017 with product launches in Hong Kong, Singapore, and the United
Kingdom. TRU NIAGEN® has received several awards as a favorite
product amongst Watsons loyalty members. TRU NIAGEN® EX stick packs
further broaden the spectrum of potential consumers.
The stick packs, which each provide 300mg nicotinamide riboside
mixed with fiber source inulin (chicory root extract), will offer
consumers single-serving packets that easily mix into both cold and
warm beverages, including smoothies and coffee. The vegetarian and
caffeine-free product is suitable for people who are looking for an
extra NAD+ boost for cellular energy and repair.
“Our customers have demonstrated a steadfast commitment to
improving their health every day, and we constantly look for ways
to provide innovative and user-friendly solutions to help,” says
Samuel Lee, Managing Director of Watsons Hong Kong. “As one of our
top selling health products, TRU NIAGEN® has been a widely sought
after supplement. We are confident that our customers will be
thrilled with the expansion of our partnership with ChromaDex as it
provides them with a new option that can be easily implemented into
any health routine.”
Supporting cellular defense and repair by boosting NAD+ levels
is important for healthy aging. NAD+ levels decline with age as
well as physiological stressors including stress on the immune
system, alcohol consumption, over-exercising, and lack of healthy
sleep cycles. NIAGEN® increases NAD+ levels safely and
efficaciously, as demonstrated in nine published human trials.
For additional information on the science supporting TRU
NIAGEN®, please visit www.truniagen.com.
For additional information on Watsons, please visit
www.watsons.com.hk.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people age. ChromaDex
scientists partner with leading universities and research
institutions worldwide to discover, develop and create solutions to
deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, NIAGEN® nicotinamide riboside, sold
directly to consumers as TRU NIAGEN®, is backed with clinical and
scientific research, as well as extensive IP protection. TRU
NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a
website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether TRU NIAGEN® EX
will help the Company reach the active, fitness-oriented consumer.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2019 as amended, ChromaDex's
Quarterly Reports on Form 10-Q and other filings submitted by
ChromaDex to the SEC, copies of which may be obtained from the
SEC's website at www.sec.gov. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005305/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024